Provided by Tiger Fintech (Singapore) Pte. Ltd.

Infinity Pharmaceuticals, Inc.

0.0160
+0.0000
Volume:- -
Turnover:- -
Market Cap:1.45M
PE:-0.03
High:0.0160
Open:0.0160
Low:0.0160
Close:0.0160
Loading ...
Feb 10, 2022

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Jan 18, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 05, 2022

Major Issues Report

8-K - Current report
Dec 10, 2021

Major Issues Report

8-K - Current report
Sep 10, 2021

Statement Of Changes In Beneficial Ownership

3 - Initial statement of beneficial ownership of securities
Sep 10, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Sep 03, 2021

Statement Of Changes In Beneficial Ownership

3 - Initial statement of beneficial ownership of securities
Sep 03, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Aug 03, 2021

Statement Of Changes In Beneficial Ownership

3 - Initial statement of beneficial ownership of securities
Aug 03, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Aug 02, 2021

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Jul 27, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Jul 27, 2021

Major Issues Report

8-K - Current report
Jun 17, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Jun 11, 2021

Major Issues Report

8-K - Current report
Jun 11, 2021

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
May 19, 2021

Correspondence

CORRESP [Cover] - Correspondence
May 13, 2021

Major Issues Report

8-K - Current report
May 13, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Mar 16, 2021

Major Issues Report

8-K - Current report